BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 28, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tanezumab: FDA hold

Pfizer suspended its osteoarthritis (OA) program for tanezumab after FDA placed it on clinical hold due to a "small number" of cases of worsening OA leading to joint replacement in tanezumab-treated patients. Pfizer said the adverse event has not been observed in non-OA patients receiving...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >